[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657497":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":31,"overallOfficials":37,"centralContacts":41,"locations":50,"responsibleParty":63,"collaborators":13,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":13,"eligibilityCriteria":70,"healthyVolunteers":67,"sex":71,"minAge":72,"maxAge":13,"enrollmentInfo":73,"targetDuration":13,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":13,"overallStatus":52,"whyStopped":13,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"NYU Langone Health","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Aegenta M-Test Score","Aegenta device output - a quantitative measure intended to capture the degree of metamorphopsia.","Day 0",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","DEVICE_FEASIBILITY",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21,27],{"label":22,"type":23,"description":24,"interventionNames":25},"Amsler-negative participants","EXPERIMENTAL","Individuals without retinal pathology and without reported visual distortion on the Amsler grid will undergo testing with the Aegenta VR device in addition to established clinical assessments used to evaluate metamorphopsia and aniseikonia.",[26],"Device: Aegenta VR",{"label":28,"type":23,"description":29,"interventionNames":30},"Amsler-positive participants","Individuals with retinal pathology associated with visual distortion, including epiretinal membrane (ERM), age-related macular degeneration (AMD), diabetic macular edema (DME), central serous retinopathy (CSR), or cystoid macular edema (CME), who report distortion on the Amsler grid, will undergo testing with the Aegenta VR device in addition to established clinical assessments used to evaluate metamorphopsia and aniseikonia.",[26],[32],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":13},"DEVICE","Aegenta VR","The Aegenta VR system is a custom software application designed to operate with a virtual reality (VR) headset platform, such as a smartphone paired with a Google Cardboard V2 viewer. The application presents visual stimuli to each eye and allows users to identify perceived distortions and magnification changes. These responses are used to generate quantitative measures of metamorphopsia and aniseikonia.",[22,28],[38],{"name":39,"affiliation":5,"role":40},"Nitish Mehta, MD","PRINCIPAL_INVESTIGATOR",[42,46],{"name":39,"role":43,"phone":44,"phoneExt":13,"email":45},"CONTACT","212-263-2573","Nitish.Mehta@nyulangone.org",{"name":47,"role":43,"phone":48,"phoneExt":13,"email":49},"Tonya Robin","929-455-5041","Tonya.Robin@nyulangone.org",[51],{"facility":5,"status":52,"city":53,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":13},"RECRUITING","New York","10016","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-74.00597,40.71427,{"lat":61,"lon":60},{"type":64,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100657497","virtual-reality-aniseikonia-and-metamorphopsia-testing-100657497",false,"NCT07838181","Virtual Reality Aniseikonia and Metamorphopsia Testing","Inclusion Criteria:\n\n* Over 18 years of age\n* Have no reported visual distortions with a negative Amsler test; or\n* Have visual distortions with a positive Amsler grid test and an ocular history of one of the following: epiretinal membrane (ERM), age-related Macular degeneration (AMD), central serous retinopathy (CSR), diabetic macular edema (DME), cystoid macular edema (CME)\n* Ophthalmology residents, staff, and physicians\n\nExclusion Criteria:\n\n* Eye pathology limiting view to the posterior pole to obtain adequate quality fundus photograph or OCT imaging in either eye\n* Impaired visual acuity with best-corrected visual acuity equal to or worse than 20\u002F70\n* Motor deficits of the upper extremities","ALL","18 Years",{"count":74,"type":75},100,"ESTIMATED","INTERVENTIONAL",[78],"NA","The purpose of this study is to assess whether the use of small, lightweight, portable virtual reality headset devices can provide a more accessible, reliable, contained, and convenient testing environment compared to previous platforms.\n\nMany tests only assess distortions in one plane or meridian and may have confounding effects from factors such as external stimuli or the use of colored filters to selectively display images to each eye. The investigators hypothesize that this device will help minimize, if not get rid of, a lot of these confounding factors that exist currently.",[81,82],"Metamorphopsia","Aniseikonia","2026-09-18",{"date":85,"type":86},"2026-09-24","ACTUAL",{"date":88,"type":86},"2026-08-04",{"date":90,"type":75},"2030-06-30",{"name":5,"class":6},1]